The FDA approved Intellia Therapeutics’ biologics license application for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR-based one-dose genome editing therapy for hereditary angioedema (HAE). The approval follows Phase III HAELO trial results published in The New England Journal of Medicine in June. Lonvo-z uses an mRNA-lipid nanoparticle delivery format designed to treat HAE, a rare genetic disorder marked by unpredictable and potentially life-threatening swelling attacks. Intellia and trial investigators described the therapy’s intent as reducing burdens associated with repeat treatments and unpredictable attacks. In the reporting, lead investigator Danny Cohn of Amsterdam University Medical Center said HAE can be disfiguring and extremely painful, especially when attacks affect the intestines, while Kelsey Uminski at the University of Calgary highlighted risks including upper-airway involvement. For the gene-editing market, this marks another milestone in transitioning CRISPR from development into routine regulatory acceptance—particularly in a medically urgent rare-disease setting.